Abstract
We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.
Original language | English |
---|---|
Pages (from-to) | 255-257 |
Number of pages | 3 |
Journal | Surgery today |
Volume | 41 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2011 |
All Science Journal Classification (ASJC) codes
- Surgery